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Abstract
Despite significant medical advances since the advent of lung transplantation, improvements in 
long-term survival have been largely unrealized. Chronic lung allograft dysfunction, in particular 
obliterative bronchiolitis, is the primary limiting factor. The predominant etiology of obliterative 
bronchiolitis involves the recipient’s innate and adaptive immune response to the transplanted 
allograft. Current therapeutic strategies have failed to provide a definitive treatment paradigm to 
improve long-term outcomes. Inducing immune tolerance is an emerging therapeutic strategy that 
abrogates allograft rejection, avoids immunosuppression, and improves long-term graft function. 
The aim of this review is to discuss the key immunologic components of obliterative bronchiolitis, 
describe the state of establishing immune tolerance in transplantation, and highlight those 
strategies being evaluated in lung transplantation.
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1. Introduction
Lung transplant remains the only definitive treatment available for many end-stage 
pulmonary disorders including chronic obstructive pulmonary disease, idiopathic pulmonary 
fibrosis, idiopathic pulmonary arterial hypertension, and cystic fibrosis [1]. The utility of 
lung transplantation as a treatment modality is reflected by the number of transplants 
performed, which has increased from 5 in 1985 to 3640 worldwide in 2011 [1]. However, 
despite dramatic improvements in surgical technique, immunosuppressive regimens, and 
coordinated patient care, the median 5 year survival among recipients is 50%, lower than 
any other solid organ allograft (Fig. 1) [1,2]. Chronic lung allograft dysfunction (CLAD), in 
general, and obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS) in 
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particular, are the predominant factor limiting long-term survival after lung transplant. 
CLAD, previously known as chronic rejection, can be represented by different histologic 
patterns with OB being the most common. OB occurs in the small conducting airways, 
sparing the more distal respiratory bronchioles. As seen in Fig. 2, partial or complete airway 
occlusion arises as a result of proliferation of connective tissue, which may include 
microvascular-rich granulation in the context of abnormal tissue repair and remodeling [3]. 
BOS is the clinical correlate of OB and is diagnosed on the basis of forced expiratory 
volume in 1 s (FEV1) [4]. Within 5 years of transplant nearly 49% of recipients have BOS, a 
number that increases to 76% at 10 years and represents the most common cause of death 
among recipients following the first post-transplant year [1]. At present, once initiated there 
is no effective treatment to reverse the obliterative process. The aim of this review is to 
describe the immunopathophysiology of OB and outline the current state of establishing 
immune tolerance in transplantation, particularly in the setting of lung allografts.
2. Immunopathophysiology of obliterative bronchiolitis
The pathogenesis of OB has not been fully characterized but is known to be multifactorial 
and includes components of cellular and humoral alloimmunity, innate immunity, and both 
cellular and humoral autoimmunity. The cellular immune response to allo- and autoantigens 
is dependent on the migration of antigen presenting cells (APCs) to secondary lymphoid 
organs, including the spleen and lung’s regional lymph nodes where reactive T cells are 
activated [5]. T cells may also be stimulated directly by dendritic cells within the lung [6]. 
As depicted in Fig. 3, T cell receptors can recognize intact allogeneic major 
histocompatibility complex (MHC) on donor cells (direct pathway), peptide fragments of 
allogeneic MHC presented by recipient MHC molecules (indirect pathway), or possibly the 
semidirect pathway that involves intact donor derived MHC-peptide complexes presented by 
recipient antigen presenting cells to recipient T cells [6,7]. However, unlike other solid 
organ transplants, there is little evidence of the semidirect pathway involved in lung 
transplant rejection. Following the recognition of MHC antigen, T cells require secondary 
costimulatory signals, which result in a cascade of secondary signaling leading to 
proliferation and differentiation. The primary T cell type responsible for ongoing immune 
reactivity includes Th1 and Th17, which are key sources of interferon-γ and IL-17, 
respectively, which facilitate further the immune response [8].
The role of humoral alloimmunity has been suggested by clinical findings where MHC 
antibodies that develop after transplant have been demonstrated to confer an increased risk 
of BOS and decreased survival [9]. The allogeneic antibody targets include MHC and minor 
histocompatibility antigens. Following transplant, T cell dependent donor specific B cells 
develop resulting in anti-donor antibody production by plasma cells. Antibodies bind their 
donor antigenic target, as well as complement factor C1q, resulting in activation of the 
complement cascade [10]. The involvement of antibody mediated rejection in OB has been 
suggested by findings that donor specific antibodies precede the onset of BOS and are 
strongly associated with its development [11]. Furthermore, it is mechanistically supported 
by studies demonstrating anti-HLA antibodies induce fibrogenic growth factor production, 
proliferative changes, and apoptotic death in airway epithelial cells [12]. However, unlike 
Gracon and Wilkes Page 2
Hum Immunol. Author manuscript; available in PMC 2015 March 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
OB that occurs in graft versus host disease post hematopoietic stem cell transplants, there is 
no direct evidence that alloantibodies, alone, induce OB post lung transplantation [13].
The innate immune response in lung transplant rejection is an emerging concept and of 
particular interest given the allograft’s unique environmental exposure. Ischemia reperfusion 
injury (IRI) following transplant has been found to induce inflammation through activation 
of toll-like receptors (TLR) and signaling via TLR signal adaptor MyD88 [14]. Primary 
graft dysfunction (PGD), thought to be at least partially induced through this pathway, has 
been associated with increased rates of BOS [15]. Furthermore, polymorphisms in TLR4 
that alter the response to endotoxin, have been associated with a trend toward reduced onset 
of BOS [16]. Our group recently confirmed that the development of OB is at least partly 
dependent on complement. It was shown that complement regulatory proteins CD55 and 
Crry (CD46) are downregulated during OB in both humans and mice, while bronchoalveolar 
lavage (BAL) fluid C3a, an anaphylotoxin, is increased. This process was found to be 
mediated by IL-17 [17].
One critical pathophysiologic feature of OB is a cycle of repeated injury and repair [18]. 
Injury may be induced by IRI, alloimmune, or innate immune responses and results in the 
release of inflammatory products, matrix metalloproteases, and other mediators that 
ultimately lead to tissue remodeling. This process of remodeling exposes autoantigens 
previously concealed from the immune system [19]. A substantial amount of work in the 
area of autoimmunity has demonstrated type V collagen [Col(V)] to be a critical self-antigen 
liberated by this process. Col(V) is present in the lung, skin, and placenta as a triple helix 
heterodimer composed of α1 and α2 chains [20]. Within the lung it is located in the 
perivascular and peribronchial tissues, as well as the epithelium – all sites of chronic 
rejection [21]. Col(V) is assembled in the same fibril as collagen Type I, effectively masking 
it’s molecular epitopes from the immune system [22]. When the lung parenchyma is 
subjected to repeated injury, these antigenic proteins are exposed allowing for an 
autoimmune response. Col(V) cellular autoimmunity has been demonstrated in both 
preclinical and clinical studies. Using a rat lung orthotopic transplant model, our laboratory 
has demonstrated T cell responses to col(V) after the onset of OB in allograft recipients, a 
response not present for third-party antigens or in naïve animals [23,24]. This finding was 
confirmed clinically by Burlingham et al. in a study of human transplant recipients. Here it 
was shown that patients with strongly positive T cell response to col(V) had the highest 
incidence of severe BOS [8].
The humoral response to self-antigen in the context of lung transplantation has also been 
explored. Autoantibodies to col(V) and K-α1 tubulin have been specifically implicated in 
the development of BOS in preclinical models [25,26]. K-α1 tubulin (Kα1T) is a protein 
component of microtubules, which provide cytoskeletal structure and are critical for normal 
cellular function [27]. Kα1T exposure may result from chronic injury to the airway 
epithelium or as a result of cell surface expression under select circumstances. Anti-Kα1T 
binding to airway epithelial cells results in expression of transcription factors involved in 
fibroproliferation, a hallmark of OB [25]. Clinically, the presence of anti-col(V) and anti-
Kα1T antibodies following transplant have been strongly correlated with the development of 
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BOS [28]. Furthermore, a subset of patients have anti-col(V) and anti-Kα1T pre-transplant, 
which confer an increased risk of BOS as well [29].
3. Immune tolerance
A critical feature of the normal immune system is establishing effective cell-mediated and 
humoral responses to foreign antigens while remaining unresponsive to self-antigens [30]. 
This occurs both centrally and peripherally as seen in Fig. 4. Central tolerance refers to 
triggered cell death of intrathymic immature CD4+ T cells with high affinity for self-antigen, 
termed negative selection. This process limits the maturation of self-reactive cells and their 
subsequent relocation to the periphery. Peripheral tolerance pertains to the regulation of 
mature T cells in peripheral tissues by anergy, deletion, and/or production of regulatory T 
cells (Tregs). Anergy represents a state of inactivation that results from insufficient 
costimulation of self-reactive T cells, while deletion likely results from apoptosis induced 
upon recognition of self-antigen [31,32]. Tregs modulate the activity of reactive T cells 
through production of regulatory cytokines that include IL-10, TGF-β, or IL-35 [33]. As a 
key regulatory immune cell, Tregs have been implicated as a mechanistic component of 
most approaches used to induce tolerance.
The goal of establishing tolerance in transplantation is to deliberately abate the detrimental 
allograft-specific immune response, while eliminating long term immunosuppression and 
maintaining a competent immune system [34]. Definitions of tolerance that may be of 
greater use clinically include clinical operational tolerance (COT) and prope tolerance. COT 
refers to “perfectly normal graft function in the total absence of maintenance 
immunosuppression” that occurs in patients that maintain “all other immune responses 
intact” [35]. Prope tolerance or “almost” tolerance refers to circumstances where normal 
graft function requires maintenance immunosuppression, albeit in very low doses [36]. In 
addition to clear definitions of tolerance, establishing biochemical indications of whether 
tolerance has occurred is of critical importance. In 2010, Newell and colleagues made 
progress in this regard by examining kidney transplant recipients who had developed 
tolerance [37]. It was demonstrated that tolerant patients had expanded numbers of NK cells 
as well as total and naïve B cells, with differential expression of three B cell genes. These 
three genes predicted tolerance with 100% accuracy in a patient test set and as a result 
represented a step forward with regard to tolerance biomarker identification. In a concurrent 
study by Sagoo and colleagues, similar findings were made with regard to the expansion of 
B and NK cells in peripheral blood of tolerant recipients [38]. Additionally, other bioassays 
revealed that tolerant individuals lacked donor-specific antibodies, had fewer activated 
CD4+ T cells and donor-specific hyporesponsiveness of CD4+ T cells, and had a high ratio 
of forkhead box P3 to α-1,2-mannosidase gene. Together, the authors offered these findings 
as a “cross-platform biomarker signature” that could be used to identify tolerant individuals 
[38].
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4. Approaches to transplant tolerance
4.1. Antigen-coupled cells
Antigen-coupled cells are developed by 1-ethyl-3-(3′-dimethyl-aminopropyl)-carbodiimide 
(ECDI) treatment of peripheral blood cells or splenocytes. This approach allows for the 
targeting of T cells with varying specificity given multiple peptides can be coupled to a 
single cell [39]. After administration, tolerance induction occurs as a result of cell apoptosis 
and uptake by the spleen, followed by T cell anergy involving IL-10, TGF-β, and 
costimulatory pathways including PD-1/PD-L1. This is followed by a Treg mediated 
maintenance phase [40,41]. Using an MHC-mismatched islet transplantation model in mice, 
Luo et al. demonstrated that ECDI-treated donor splenocytes administered to recipients pre 
and post-transplant resulted in prolonged allograft tolerance without immunosuppression 
[42]. This included a complete absence of donor-specific antibodies and delayed-type 
hypersensitivity (DTH) response among tolerized recipients. This approach was further 
evaluated in a fully MHC-mismatched cardiac allograft model, where tolerance was 
achieved when ECDI was combined with a short course of rapamycin [43]. Recently, a 
phase I clinical study sought to evaluate antigen-coupled cells for the treatment of 
autoimmune disease [44]. Here it was shown that multiple sclerosis (MS) patients who 
received higher doses of autologous peripheral blood mononuclear cells coupled with 
myelin peptides had decreased antigen specific T cell response. Furthermore, the safety 
profile and tolerability was found to be acceptable.
4.2. TCR/CD3 complex targeting
The T cell receptor (TCR) recognizes antigenic peptides presented by MHC of APCs. 
However, the TCR lacks the ability to transmit intracellular signals without CD3. Therefore, 
expression of TCR occurs in combination with CD3 and combined their respective protein 
chains form the TCR complex. The intracellular domain of CD3 chains contain 
immunoreceptor tyrosine-based activation motifs (ITAMs) that allow signaling to occur 
upon binding of the TCR [45]. Antibody targeting of the TCR/CD3 complex was initially 
thought of as a non-specific approach to immune suppression, however subsequent studies 
have found that antigen specific tolerance can be achieved. This process is thought to 
involve a shift to Th2 cytokine production of IL-4, reactive T cell deletion, and induction of 
Tregs [46]. Using a mouse IgG3 monoclonal antibody to CD3, Nicolls et al. first 
demonstrated the ability to achieve tolerance using monoclonal anti-CD3 antibody in a rat 
cardiac transplantation model [47]. Here it was shown that anti-CD3 mAb induced a state of 
long-term immune unresponsiveness to fully MHC incompatible cardiac allografts. 
Furthermore, treated rats were unresponsive to subsequent donor strain skin grafts, with skin 
graft survival up to 150 days in the absence of immunosuppression. Anti-CD3-induced 
immune tolerance has also been achieved in a murine pancreatic islet transplantation model 
[48]. C57BL/6 mice receiving pancreatic islets from BALB/c donors had >100 day allograft 
acceptance if treated with anti-CD3. The timing of antibody administration was found to be 
critical as delayed administration significantly prolonged survival. This finding suggested 
that a primed immune system was necessary for anti-CD3 antibody mediated tolerance. To 
date, translation to the clinic has focused on autoimmune processes, namely Type I 
Diabetes. This has included Phase I, II, and III studies of otelixizumab and teplizumab, 
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humanized Fc mutated antibodies to CD3, where short treatment courses have conferred 
benefit with regard to maintenance of insulin secretion for up to 24 months when adequately 
dosed [49]. However, because differences exist between the autoimmune response to 
pancreatic cells that occurs with diabetes and the immune response to transplanted allograft, 
further studies will be required to demonstrate the utility of anti-CD3 antibody in the 
transplant population.
4.3. T cell costimulation blockade
T cell activation is a regulated process requiring secondary signaling in combination with 
cognate interactions of the T cell receptor with MHC expressed on antigen presenting cells. 
A variety of therapeutic targets involving costimulatory signaling have been evaluated for 
use in the induction of immune tolerance. The CD28:CD80/CD86 pathway represents the 
most frequently studied target and involves CD80 (B7-1) and CD86 (B7-2) on the surface of 
APCs binding CD28 on T cells. Binding of CD28 is required for T cell activation to occur 
following antigen presentation to the TCR. CD80 and CD86 are also involved in a second, 
coinhibitory pathway, that occurs as a result of binding to cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4 also known as CD152) on previously activated T cells [50]. 
CTLA-4 is structurally similar to CD28, but binds CD80 and CD86 with significantly higher 
affinity. Therefore CD28 costimulatory signaling is interrupted leading to incomplete T cell 
activation, anergy, and apoptosis [51]. Capitalizing on this pathway has included anti-CD80/
CD86 monoclonal antibodies, anti-CD28 monoclonal antibodies, and CTLA-4 
immunoglobulin (Ig) fusion proteins [52]. Blocking CD80/86 has been shown to result in 
prolonged allograft survival in a non-human primate (NHP) model of renal transplantation. 
However, even when combined with other immunosuppressant agents, this approach has not 
been shown to achieve tolerance [53]. Conversely, Haspot et al. demonstrated that anti-
CD28 administered immediately following transplant resulted in renal allograft tolerance 
among fully MHC mismatched rats [54].
CTLA-4-Ig, comprised of the Fc domain of human IgG1 linked to the extracellular 
component of CTLA-4, represents the most thoroughly studied approach to inducing 
immune tolerance with costimulatory blockade. Early studies demonstrated that CTLA-4-Ig 
could abrogate T cell dependent B cell antibody production and limit rejection of cardiac 
allografts [55]. This was followed by Pearson and colleagues who demonstrated tolerance 
among mouse cardiac allograft recipients. Here it was shown that the majority of recipients 
receiving a 12 day course of CTLA-4-Ig following transplant with fully mismatched grafts 
resulted in indefinite (>100 day) survival. Donor specific tolerance was subsequently 
confirmed by acceptance of donor-specific skin grafts while third-party grafts were rejected 
[56]. Despite promising results in these rodent transplant models, among others, CTLA-4-Ig 
was unable to induce tolerance in NHP and humans. With modification however, it was 
translated to the clinic as belatacept and approved for use with renal transplantation 
induction and maintenance.
The CD40:CD154(CD40L) pathway represents a second extensively studied target for 
extending allograft survival. CD40 is expressed on B cells, APCs, and macrophages. 
Endothelial expression may also be induced as a result of inflammation [52]. CD154 is 
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expressed on T cells following antigen induced activation. Cell-surface CD154 or soluble 
CD154 binding to CD40 results in signaling via tumor necrosis receptor associated factor 
(TRAF) and nuclear factor-κB (NF-κB) pathways. This serves to promote antigen 
presentation and cytokine production, further activating T cells. Similarly, binding to B cells 
is essential for antibody production and proliferation [57,58]. The therapeutic potential of 
this pathway has been clearly established in small animal models. Hancock et al. 
demonstrated that by combining anti-CD154 with donor specific transfusions, allograft 
function was extended beyond 150 days in a cardiac allograft rat model [59]. Combining 
anti-CD154 mAb and CTLA-4-Ig, Larson et al. showed a synergistic effect could be 
realized. Using this approach, he was able to demonstrate a greater than 50 day survival of 
fully mismatched murine skin allografts, as well as inhibition of chronic vasculopathy in the 
cardiac allograft model [60]. Jiang et al. confirmed the finding of extended cardiac graft 
survival in this model and further demonstrated tolerance was attributable to donor Tregs, 
which were critical following transplant, but not required for maintenance of tolerance [61]. 
Despite further successes with anti-CD154 mAb in multiple models including NHP, 
translation to the clinic was limited by thromboembolic events. This was an unintended 
consequence of antibody interaction with CD154 on platelets which lead to platelet 
activation and subsequent vascular compromise [62]. As a result, targeting this pathway has 
shifted to the use of anti-CD40 mAb. This alternative approach has also shown promising 
results. Combining anti-CD40, anti-CD86, and a short course of low dose cyclosporine, 
Haanstra et al. demonstrated prolonged survival of renal allografts in rhesus monkeys [63]. 
In this study, two of four animals had 3-year drug free survival following initial treatment.
Given these successes, additional pathways of interest for mitigating the immune response in 
transplant continue to emerge. These include inducible T cell costimulator (ICOS), 
programmed cell death protein 1 (PD-1 or CD279), OX40 (CD134), 4-1BB (CD137), CD27, 
lymphocyte function-associated antigen 1 (LFA-1), CD2, T cell Ig and mucin 1 (TIM-1), 
B7-H3/4 and their respective ligands [64].
4.4. Mixed chimerism
Mixed chimerism refers to transplantation of hematopoietic stem cells to a recipient 
establishing a coexistent host and donor lymphohematopoietic system [7]. Early murine 
studies by Illstad and Sachs were the first to demonstrate the utility of this approach in 
transplant tolerance [65]. It was shown that mice undergoing irradiation followed by mixed 
donor and recipient lymphohematopoietic reconstitution accepted subsequent donor type 
skin grafts while rejecting third-party allografts. Achieving these results in mice has 
historically required recipient cytoablative conditioning with complete destruction of mature 
donor-reactive T cells. However, new protocols and techniques, including the use 
costimulatory blockade, have helped to improve the toxicity profile [66]. As reviewed by 
Sachs, Kawai, and Sykes, establishing tolerance by inducing mixed chimerism has had 
success in preclinical and clinical studies and has been the most successfully translated 
strategy for transplant tolerance to date [66]. This is exemplified by Kawai’s study of end-
stage renal disease patients receiving combined bone marrow and kidney transplants [67,68]. 
Following conditioning, five patients received living related kidneys donated by relatives 
that were mismatched for one HLA haplotype. The conditioning regimen included 
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preoperative cyclophosphamide, anti-CD2 mAb, and thymic irradiation. Following 
transplant, subjects received donor bone marrow and several months of cyclosporine. This 
protocol was changed during the study to also include preoperative rituximab and a short 
postoperative course of prednisone. All patients developed transient chimerism and four of 
the five patients were withdrawn from all immunosuppressive agents by 9–14 months. Three 
of the four patients remained free from immunosuppression for over 5 years and one 
developed chronic rejection at year 5. The regimen used for these patients was further 
modified to include two additional doses of rituximab and studied in five subsequent 
patients. Three were able to discontinue immunosuppression and were free from rejection at 
the 3 year mark [68]. With these promising results, this strategy may prove the closest to 
expanded clinical use.
4.5. Regulatory cells
Several groups of “suppressive” or T regulatory cells have been found in vivo or induced 
experimentally. The most frequently occurring and well defined Treg is the CD4+ CD25+ 
Foxp3+ cell. Tregs are a critical component of the normal immune system’s ability to remain 
homeostatic, which is accomplished by the release of immunomodulatory cytokines, as well 
as direct cell–cell interactions [69,70]. This serves to balance the activated immune 
response, which becomes increasingly important in the context of a transplanted allograft. 
Preclinical models, as well as clinical lung transplantation have shown that increased 
proportions of Tregs confer stable allograft function, while a decline of this cell population 
is associated with chronic rejection [70]. Nearly every strategy to induce allograft tolerance 
relies on Tregs as a component of induction or long-term maintenance. As a result, therapy 
incorporating in vivo activation or adoptive transfer of Tregs has become a significant focus. 
Using a fully MHC-mismatched murine islet transplantation model, Lee et al. demonstrated 
that indefinite graft survival could be achieved. Recipient mice were conditioned with a 
transfusion of donor splenocytes followed by cyclophosphamide. Donor specific Tregs were 
expanded in vitro and administered prior to transplantation. More than 70% of recipients 
achieved indefinite graft survival without additional immunosuppression [71]. Joffre et al. 
incorporated Tregs to induce tolerance to skin and cardiac allografts [72]. Here, in vitro 
expansion of Tregs specific for both direct and indirect alloantigen presentation were used in 
conjunction with bone marrow to establish a chimeric state in recipients. Subsequently 
placed allogeneic skin grafts survived to 100 days without histologic evidence of rejection. 
Using a similar protocol, equivalent results were demonstrated with cardiac allografts. One 
significant advantage of using Tregs in the setting of mixed chimerism is the ability to avoid 
toxic cytoreductive conditioning of the recipient, a requirement of many chimerism 
induction protocols [73].
The ability to translate these results into an effective therapy will depend heavily on reliable 
Treg production with adequate purity and stability, as well as documentation of safety. Early 
phase studies have been initiated to evaluate Treg therapy in the clinic, including studies in 
graft versus host disease, liver transplantation, and kidney transplantation [74]. These initial 
studies will provide the preliminary results necessary to evaluate the feasibility of this 
strategy moving forward for other solid organ allografts, including the lung.
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4.6. Oral immunotherapy
Oral immunotherapy (OIT) refers to the oral administration of an antigen with the goal of 
suppressing a subsequent immune response to the same antigen [75]. Mucosal 
administration of peptides for antigen-specific induction of tolerance highlights the body’s 
inherent ability to interact with non-self antigens. The gastrointestinal tract mucosa is 
exposed to a myriad of foreign antigens originating from the bacterial microbiome and 
foreign ingestion. Despite this, a state of non-pathologic homeostasis is maintained [76]. 
Advantages of OIT include ease of preparation, administration, and decreased toxicity. 
Preclinical studies evaluating the use of OIT in models of autoimmune disease including 
multiple sclerosis, diabetes, and arthritis have shown encouraging results with regard to 
mitigating the disease process. Two dominant contributory mechanisms have been 
identified: (1) secretion of modulatory cytokines by Tregs and (2) clonal deletion or anergy 
of antigen specific T cells [77]. In transplantation, this approach has a distinct advantage 
compared to autoimmune processes given allo and autoantigens have been defined and may 
be administered prior to the recipient immune system’s detrimental effects [78]. The first 
report describing the oral administration of MHC antigen and its effect on the systemic 
alloimmune response was by Sayegh et al. Here it was shown that feeding allogeneic 
splenocytes prevented sensitization to skin allografts and altered cardiac allograft rejection, 
slowing the pace of rejection from “accelerated” to acute [79]. The group also demonstrated 
an antigen-specific tolerogenic effect following the oral administration of synthetic class II 
MHC peptides, where it was shown that the DTH response to peptides and donor-derived 
cells was inhibited [80]. Niimi et al. combined the oral administration of alloantigen with 
anti-CD4 monoclonal antibody. Using this technique, cardiac allografts survived indefinitely 
in recipient mice [81]. A subsequent pilot study initiated by Womer and colleagues 
incorporated oral administration of class II MHC peptides in a cohort of renal transplant 
recipients who had evidence of alloreactivity and epitope spreading [78]. Complete 
suppression of alloreactivity was achieved and safety of administration confirmed. As with 
other models of OIT, the dose was found to be of critical importance illustrated by efficacy 
at a low dose, but not at higher doses.
5. Lung transplant tolerance
Lung allografts are particularly immunogenic. This is evidenced by higher rates of rejection 
and decreased survival compared to other solid organs. The etiology of their 
immunogenicity is multifactorial, including repeated exposure to infective and noninfective 
stimuli in inspired air, as well as microaspiration [82]. As a result, establishing immune 
tolerance has been limited compared to other organs. This was illustrated by Gelman et al. 
who demonstrated that costimulatory blockade with CTLA-4-Ig alone was incapable of 
producing prolonged survival of pulmonary allografts in a murine vascularized lung 
transplant model [83]. This is in contrast to previous successes with this approach in other 
murine organ transplantation models. Similarly, inducing mixed chimerism has yielded 
worse outcomes among lung allograft recipients despite significant success with renal 
allograft transplantation. This was elucidated by Aoyama et al. who utilized fully MHC 
mismatched cynomolgus monkeys [84]. With a protocol previously successful with renal 
allografts, recipients were conditioned with total body irradiation, thymic irradiation, and 
Gracon and Wilkes Page 9
Hum Immunol. Author manuscript; available in PMC 2015 March 12.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
anti-thymocyte globulin. Following transplant, each received anti-CD154 and a short course 
of cyclosporine. Transient chimerism was achieved, but allografts were rejected in a 
significantly shorter time period than what was observed in kidneys transplanted under the 
same conditions.
Despite these results, several approaches have shown various degrees of success in lung 
transplantation models. Using the mouse orthotopic lung transplant model, Dodd-O et al. 
demonstrated that costimulation blockade with anti-CD154 Ab abrogated the alloeffector 
CD8+ and CD4+ responses. This included an increase in the CD4:CD8 ratio with a higher 
frequency of CD4+ CD25+ Foxp3+ T cells [85]. Okazaki et al. confirmed the utility of 
costimulation blockade in the allogeneic lung transplant model using anti-CD154 with 
prolonged survival of allogeneic lung grafts in excess of 100 days [86]. Using MHC class I 
disparate inbred miniature swine, Shoji et al. demonstrated that a 12 day post-operative 
course of continuous intravenous tacrolimus without further immunosuppression resulted in 
long term lung graft survival without evidence of chronic rejection [87]. This was followed 
by a study with full MHC disparity with similar graft longevity, but some evidence of OB on 
pathology [88]. A recent development in the prevention of OB includes the use of 
mesenchymal stem cells. Using a heterotopic tracheal transplant model, Zhao et al. showed 
that placenta derived human mesenchymal stem cells (PMSCs) attenuated the development 
of obliterative airways disease that shares some histologic features with OB [89]. PMSCs 
were administered to the peri-graft subcutaneous tissue following transplant and based on 
group assignment, the tracheas were harvested at 14 and 28 days. Significant differences 
were found in luminal obliterations as well as Treg concentration. These preliminary results 
suggest this approach may have utility, however due to differences between the heterotopic 
tracheal transplant model and the ventilated and perfused orthotopic lung transplant model, 
further investigation is warranted to validate these findings [90,91].
Our laboratory has utilized concepts introduced in the field of autoimmune disease to 
explore the use of autoantigen OIT in transplantation. Col(V) was initially selected as a 
tolerizing antigen due to the brisk anti-col(V) T cell mediated immune response that 
occurred following lung transplantation in rats [92]. Early experiments employed a rat 
model of transplantation where WKY (RT1lv1) rats served as recipients and were fed col(V) 
prior to transplantation of F344 rats (RT1l) lung allografts. Oral administration of col(V) 
was found to prevent both acute rejection and OB in the absence of any other form of 
immunosuppression [23,24]. Similar to models of autoimmune disease, suppression of the 
immune response in the transplant recipient was found to be associated with increased TGF-
β. However, contrary to findings in autoimmune models, IL-10 and IL-4 were not detected 
[24]. These findings instigated the study of rat lung allografts fully incompatible at MHC 
class I and II loci. Brown Norway (RT1n) lungs were transplanted into WKY (RT1lv1) rats 
and comparison was made with col(V) oral administration and cyclosporine versus 
cyclosporine alone. Compared to cyclosporine alone, col(V) oral administration plus 
cyclosporine prevented rejection and down-regulated the alloantigen-induced production of 
IFN-γ and IL-17A. Additionally, chemotaxis for lung macrophages was suppressed in 
allograft bronchoalveolar lavage fluid. The combination was also associated with Treg 
involvement including expression of IL-10 in mediastinal lymph node and splenic T cells, 
intragraft expression of IL-10 and Foxp3 in perivascular and peribronchiolar mononuclear 
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cells, and production of IL-10 from allograft alveolar macrophages [93]. Interestingly, this 
study did not identify an association with TGF-β as part of the immunoregulatory pathways.
6. Conclusion
Despite incredible advances, each therapeutic strategy to induce tolerance has unique 
obstacles to overcome. Additionally, evidence clearly demonstrates that the degree of 
success will depend on the organ transplanted. Compared to other solid organs, lung 
allograft recipients have the shortest mean survival following transplant. Studies to date 
suggest that they may also represent the most challenging population for tolerance induction. 
However, this suggests that potential lung transplant recipients represent the population 
most likely to benefit from a successful therapeutic approach.
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Fig. 1. 
Graft survival: collaborative transplant study data comparing graft survival for solid organ 
allografts. Used with permission.
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Fig. 2. 
Obliterative bronchiolitis histologic specimen: lung specimen demonstrating characteristic 
occlusion of the bronchiolar lumen in obliterative bronchiolitis.
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Fig. 3. 
Alloantigen recognition: direct recognition of antigen presented by allogeneic MHC on 
donor APC, indirect recognition of antigen presented by recipient MHC on recipient APC, 
and semidirect recognition of antigen presented by allogeneic MHC on recipient APC.
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Fig. 4. 
Central and peripheral immune tolerance: central tolerance illustrated by immature 
lymphocyte recognition of self antigen resulting in apoptosis. Peripheral tolerance illustrated 
by mature lymphocyte recognition of self antigen resulting in T regulatory cell suppression, 
apoptosis, or anergy.
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